158 related articles for article (PubMed ID: 21658147)
21. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes.
Dennison JB; Mohutsky MA; Barbuch RJ; Wrighton SA; Hall SD
J Pharmacol Exp Ther; 2008 Oct; 327(1):248-57. PubMed ID: 18650247
[TBL] [Abstract][Full Text] [Related]
22. Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine.
Hartman A; van den Bos C; Stijnen T; Pieters R
Cancer; 2006 Mar; 106(6):1395-401. PubMed ID: 16453332
[TBL] [Abstract][Full Text] [Related]
23. Dexamethasone as a probe for vinorelbine clearance.
Puisset F; Dalenc F; Chatelut E; Cresteil T; Lochon I; Tisnes P; Roché H
Br J Clin Pharmacol; 2005 Jul; 60(1):45-53. PubMed ID: 15963093
[TBL] [Abstract][Full Text] [Related]
24. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
Wong M; Balleine RL; Collins M; Liddle C; Clarke CL; Gurney H
Clin Pharmacol Ther; 2004 Jun; 75(6):529-38. PubMed ID: 15179407
[TBL] [Abstract][Full Text] [Related]
25. Vincristine pharmacokinetics after repetitive dosing in children.
Gidding CE; Meeuwsen-de Boer GJ; Koopmans P; Uges DR; Kamps WA; de Graaf SS
Cancer Chemother Pharmacol; 1999; 44(3):203-9. PubMed ID: 10453721
[TBL] [Abstract][Full Text] [Related]
26. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
[TBL] [Abstract][Full Text] [Related]
27. Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate.
Israels T; Damen CW; Cole M; van Geloven N; Boddy AV; Caron HN; Beijnen JH; Molyneux EM; Veal GJ
Eur J Cancer; 2010 Jul; 46(10):1841-7. PubMed ID: 20382523
[TBL] [Abstract][Full Text] [Related]
28. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
[TBL] [Abstract][Full Text] [Related]
29. Selective metabolism of vincristine in vitro by CYP3A5.
Dennison JB; Kulanthaivel P; Barbuch RJ; Renbarger JL; Ehlhardt WJ; Hall SD
Drug Metab Dispos; 2006 Aug; 34(8):1317-27. PubMed ID: 16679390
[TBL] [Abstract][Full Text] [Related]
30. Vincristine: Can its therapeutic index be enhanced?
Moore A; Pinkerton R
Pediatr Blood Cancer; 2009 Dec; 53(7):1180-7. PubMed ID: 19588521
[TBL] [Abstract][Full Text] [Related]
31. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.
Ceppi F; Langlois-Pelletier C; Gagné V; Rousseau J; Ciolino C; De Lorenzo S; Kevin KM; Cijov D; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
Pharmacogenomics; 2014 Jun; 15(8):1105-16. PubMed ID: 25084203
[TBL] [Abstract][Full Text] [Related]
32. Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer.
Bradfield SM; Sandler E; Geller T; Tamura RN; Krischer JP
Pediatr Blood Cancer; 2015 Jun; 62(6):1004-10. PubMed ID: 25545757
[TBL] [Abstract][Full Text] [Related]
33. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.
McClain CA; Bernhardt MB; Berger A; Bernini JC; Marquez-Do D; Winslow R; Scheurer ME; Schafer ES
Br J Haematol; 2018 Jun; 181(5):684-687. PubMed ID: 28419449
[No Abstract] [Full Text] [Related]
35. Genetic factors influencing the development of vincristine-induced neurotoxicity.
Pozzi E; Fumagalli G; Chiorazzi A; Canta A; Cavaletti G
Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):215-226. PubMed ID: 33283553
[No Abstract] [Full Text] [Related]
36. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients.
Renbarger JL; McCammack KC; Rouse CE; Hall SD
Pediatr Blood Cancer; 2008 Apr; 50(4):769-71. PubMed ID: 18085684
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study.
Zgheib NK; Ghanem KM; Tamim H; Aridi C; Shahine R; Tarek N; Saab R; Abboud MR; El-Solh H; Muwakkit SA
Pharmacogenet Genomics; 2018 Aug; 28(8):189-195. PubMed ID: 30119132
[TBL] [Abstract][Full Text] [Related]
38. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.
Li JL; Wang XD; Chen SY; Liu LS; Fu Q; Chen X; Teng LC; Wang CX; Huang M
Pharmacogenomics J; 2011 Aug; 11(4):300-6. PubMed ID: 20514078
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients.
Yang XM; Ye PP; Liu XL; Guo ZX; Kan M; Li Q; Song LL; Liu HY; Chen KG; Shi JY; Zhang YH; Li Y; Zhao FR; van den Anker J; Li Y; Zhao W
Br J Clin Pharmacol; 2023 Jun; 89(6):1862-1872. PubMed ID: 36662574
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.
Fanta S; Niemi M; Jönsson S; Karlsson MO; Holmberg C; Neuvonen PJ; Hoppu K; Backman JT
Pharmacogenet Genomics; 2008 Feb; 18(2):77-90. PubMed ID: 18192894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]